These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35573364)

  • 21. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
    Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
    JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
    Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
    BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice.
    Fagiolini A; Aguglia E; Ballerini A; Callista G; Carpiniello B; Clerici M; Corrivetti G; De Fazio P; De Filippis S; De Giorgi S; Favaretto G; Ferri E; Gargiulo G; Giustra MG; La Barbera D; Maina G; Mencacci C; Montagnani G; Panariello A; Pigato G; Tortorella A; Vernacotola L; Vita A
    Psychiatry Res; 2019 Feb; 272():698-706. PubMed ID: 30832189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.
    Wilson M; Gutierrez B; Offord SJ; Blanchette CM; Eramo A; Earnshaw S; Kamat SA
    Drugs Context; 2016; 5():212273. PubMed ID: 27114739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
    Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
    J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists.
    Fagiolini A; Alfonsi E; Amodeo G; Cenci M; Di Lella M; Farinella F; Ferraiuolo F; Fraguas D; Loparco N; Gutierrez-Rojas L; Mignone ML; Pataracchia G; Pillai G; Russo F; Sanchez-Gistau V; Spinogatti F; Toscano M; Villari V; De Filippis S
    Expert Opin Drug Saf; 2016; 15(4):449-55. PubMed ID: 26886162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.
    Such P; Olivares JM; Arias L; Troels Berg M; Madera J
    Neuropsychiatr Dis Treat; 2021; 17():1881-1892. PubMed ID: 34140772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.
    De Hert M; Eramo A; Landsberg W; Kostic D; Tsai LF; Baker RA
    Neuropsychiatr Dis Treat; 2015; 11():1299-306. PubMed ID: 26064048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.
    Giordano G; Tomassini L; Cuomo I; Amici E; Perrini F; Callovini G; Carannante A; Kotzalidis GD; De Filippis S
    Front Psychiatry; 2019; 10():935. PubMed ID: 31969843
    [No Abstract]   [Full Text] [Related]  

  • 32. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
    Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
    Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.
    Sapin C; Hartry A; Kamat SA; Beillat M; Baker RA; Eramo A
    Drugs Context; 2016; 5():212301. PubMed ID: 27708677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 37. Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study.
    Waters HC; Touya M; Wee SN; Ng M; Thadani S; Surendran S; Rentería M; Rush AJ; Patel R; Sarkar J; Fitzgerald HM; Han X
    Curr Med Res Opin; 2023 Feb; 39(2):299-306. PubMed ID: 36380678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
    Margolese HC; Boucher M; Therrien F; Clerzius G
    BMC Psychiatry; 2022 Dec; 22(1):773. PubMed ID: 36482352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study.
    Sanchez-Gistau V; Moreno MJ; Gómez-Lus S; Sicras-Mainar A; Crespo-Facorro B
    Front Psychiatry; 2023; 14():1207307. PubMed ID: 37599866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Neuropsychiatr Dis Treat; 2015; 11():2299-307. PubMed ID: 26366084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.